Article
Oncology
Huijuan Lv, Yue Fei, Wei Li, Yi Wang, Jinni Wang, Jin He, Xianming Liu, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Qiongli Zhai, Xiubao Ren, Dehui Zou, Qingqing Cai, Xianhuo Wang, Huilai Zhang
Summary: A novel prognostic model integrating clinical and immune parameters, IRPI, showed better prognostic performance for risk classification of MCL patients compared to traditional MIPI.
HEMATOLOGICAL ONCOLOGY
(2022)
Review
Oncology
Hailing Liu, Xiao Shi, Huizi Fang, Lei Cao, Yi Miao, Xiaoli Zhao, Wei Wu, Wei Xu, Jianyong Li, Lei Fan
Summary: This study systematically reviewed the use of autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma (MCL) and found that the benefit of ASCT has been weakened in the era of rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HiDAC) treatment. Alternative first-line maintenance strategies should be explored.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Colleen A. Ramsower, Allison Rosenthal, Ryan S. Robetorye, Raphael Mwangi, Matthew Maurer, Diego Villa, Tim McDonnell, Andrew Feldman, Jonathon B. Cohen, Thomas Habermann, Elias Campo, Guillem Clot, Marco M. Buhler, Marta Kulis, Jose Ignacio Martin-Subero, Eva Gine, James R. Cook, Brian Hill, Philipp W. Raess, Klaus H. Beiske, Alexander Reichart, Sylvia Hartmann, Harald Holte, David Scott, Lisa Rimsza
Summary: In this study, a comprehensive comparison of clinicopathological features in older mantle cell lymphoma (MCL) patients was undertaken. The strongest prognostic indicators were identified as the simplified MCL international prognostic index (s-MIPI) and MCL35, along with blastoid cytology. Combining MIPI with MCL35 to assess proliferation may be an effective method for risk stratification in older MCL patients in future clinical trials.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Marta Pena, Maria Queralt Salas, Alberto Mussetti, Gabriel Moreno-Gonzalez, Anna Bosch, Beatriz Patino, Laura Jimenez, Meriem Kara, Rocio Parody, Anna Sureda
Summary: The study demonstrates that EASIX-PRE can predict ICU admission, overall survival, and nonrelapse mortality in patients undergoing alloHCT. Analyzing EASIX-PRE values can help identify high-risk patients, allowing for early recognition and personalized intervention to improve outcomes.
Article
Oncology
Fabrizio Huwyler, Rebekka Kunz, Ulrike Bacher, Michele Hoffmann, Urban Novak, Michael Daskalakis, Yara Banz, Thomas Pabst
Summary: Adding bortezomib to standard BeEAM HDCT in MCL patients may result in significant toxicities, particularly neuropathy, and the therapeutic efficacy is modest, suggesting the need for alternative treatment options.
Article
Hematology
Peter A. Riedell, Mehdi Hamadani, Kwang W. Ahn, Carlos Litovich, Claudio G. Brunstein, Amanda F. Cashen, Jonathon B. Cohen, Narendranath Epperla, Brian T. Hill, Annie Im, David J. Inwards, John Lister, John M. McCarty, Sai Ravi Kiran Pingali, Mazyar Shadman, Paul Shaughnessy, Melhem Solh, Patrick J. Stiff, Julie M. Vose, Mohamed A. Kharfan-Dabaja, Alex F. Herrera, Craig S. Sauter, Sonali M. Smith
Summary: In young and fit patients with mantle cell lymphoma, intensive induction therapy followed by autologous haematopoietic cell transplant is the standard care. Time to relapse after autoHCT has a significant impact on overall survival, with early relapse defining a high-risk group with inferior post-relapse survival. This study highlights the importance of considering novel therapeutic approaches for MCL patients suffering early relapse after upfront autoHCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Malte Roerden, Stefan Wirths, Martin Soekler, Wolfgang A. Bethge, Wichard Vogel, Juliane S. Walz
Summary: High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (Auto-HSCT) is a standard frontline treatment for fit mantle cell lymphoma (MCL) patients. However, lymphoma cell contamination of stem cell grafts may lead to poor outcomes. Analyzing residual MCL cells in autologous grafts can improve risk assessment for MCL patients undergoing Auto-HSCT.
Article
Hematology
Yue-Hua Zhang, Li-Min Gao, Xiao-Yu Xiang, Wen-Yan Zhang, Wei-Ping Liu
Summary: This study aimed to investigate the optimal cut-off value for p53 in predicting prognosis of MCL patients and the feasibility of using computer image analysis to determine the positive rate of p53. The results showed that setting the cut-off value of p53 at 20% can effectively predict the prognosis of MCL patients. Additionally, computer image analysis can replace semiquantitative estimation and has better prospects in MCL.
ANNALS OF HEMATOLOGY
(2022)
Article
Multidisciplinary Sciences
Chen Tian, Yueyang Li, Su Liu, Zehui Chen, Yizhuo Zhang, Yong Yu, Hongliang Yang, Haifeng Zhao, Zhigang Zhao, Tian Yuan, Yafei Wang
Summary: The study compared outcomes of aggressive B-cell NHL patients treated with IEAC or BEAC regimens followed by ASCT. Results showed that the IEAC regimen was slightly more advantageous in terms of tolerability and survival compared to the BEAC regimen, but no significant differences were observed in DLBCL or MCL patients. Multivariate analysis indicated that disease staging, survival score, lactate dehydrogenase level, disease remission, and treatment regimen were associated with patient prognosis.
SCIENTIFIC REPORTS
(2021)
Article
Cell Biology
Fei Qi, Wenyuan Zhou, Yan Xie, Yan Sun, Meng Wu, Yue Chai, Bo Chen, Ningjing Lin, Weiping Liu, Ning Ding, Yexiong Li, Mei Dong, Yuqin Song, Jun Zhu
Summary: This study aimed to assess the association between induction chemotherapy response and survival in localized extranodal NK/T-cell lymphoma (NKTCL) patients and explore a response-adapted treatment strategy. The results showed that deep remission was associated with favorable survival, and intensified chemotherapy could improve the survival of patients who did not achieve complete remission after induction chemotherapy.
Article
Radiology, Nuclear Medicine & Medical Imaging
Michael Winkelmann, Viktoria Blumenberg, Kai Rejeski, Veit L. Buecklein, Michael Ruzicka, Marcus Unterrainer, Christian Schmidt, Franziska J. Dekorsy, Peter Bartenstein, Jens Ricke, Michael Von Bergwelt-Baildon, Marion Subklewe, Wolfgang G. Kunz
Summary: This study examines the prognostic value of the International Metabolic Prognostic Index (IMPI) for patients with B-cell non-Hodgkin's lymphoma receiving CD19 chimeric antigen receptor T-cell therapy (CART). The study finds that IMPI has predictive value for progression-free survival (PFS) but not overall survival (OS) in the context of CART.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Qiang Zeng, Hang Zhang, Pu Kuang, Jian Li, Xinchuan Chen, Tian Dong, Qiuhui Wu, Chuanli Zhang, Chunping Chen, Ting Niu, Ting Liu, Zhigang Liu, Jie Ji
Summary: The conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan (ChiCGB) was effective in improving the prognosis of patients with peripheral T-cell (PTCL) or lymphoblastic T-cell lymphoma (T-LBL) undergoing autologous stem cell transplantation (ASCT). The regimen resulted in favorable overall survival and progression-free survival, with manageable adverse events. Randomized controlled trials are needed to further evaluate ChiCGB as a conditioning regimen for ASCT.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Fei Liu, Bingxin Gu, Nan Li, Herong Pan, Wen Chen, Ying Qiao, Shaoli Song, Xiaosheng Liu
Summary: Age and the heterogeneity index derived from baseline PET/CT parameters were significantly correlated with PFS in MCL patients. B symptoms were associated with OS. Other clinicopathologic index and PET/CT metabolic parameters were not related to outcome survival in MCL.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Juan P. Alderuccio, Eduardo E. Saul, Sunil G. Iyer, Isildinha M. Reis, Alvaro J. Alencar, Joseph D. Rosenblatt, Izidore S. Lossos
Summary: The long-term combined results of two clinical trials implementing R-MACLO-IVAM induction followed by thalidomide or rituximab maintenance in untreated mantle cell lymphoma (MCL) patients showed a high rate of complete response and good progression-free and overall survival rates. This treatment regimen was effective for inducing long-term remission without the need for stem cell transplantation consolidation in MCL patients.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Cell Biology
Hui Yu, Lan Mi, Fei Qi, Xing Wang, Yingying Ye, Miaomiao Li, Dedao Wang, Ning Ding, Xiaogan Wang, Yuqin Song, Jun Zhu, Yan Xie
Summary: This study investigated the long-term prognosis and prognostic factors of T-cell lymphoblastic lymphoma patients treated with first-line dose-adjusted BFM-90 regimen. It was found that survival probability improved significantly with every additional year survived, and patients who underwent APBSCT transplantation had better survival rates. Baseline NLR >= 4.95 was identified as an independent risk factor for patients.
Article
Biophysics
Sherilyn A. Tuazon, Brenda M. Sandmaier, Theodore A. Gooley, Darrell R. Fisher, Leona A. Holmberg, Pamela S. Becker, Sally J. Lundberg, Johnnie J. Orozco, Ajay K. Gopal, Brian G. Till, David G. Coffey, Margaret E. Nartea, Manuela C. Matesan, John M. Pagel, Joseph G. Rajendran, Oliver W. Press, William Bensinger, Damian J. Green
Summary: The study shows that incorporating CD45-targeted radioimmunotherapy (RIT) into reduced-intensity allogeneic HCT is well-tolerated and may induce long-term remissions in high-risk multiple myeloma patients.
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Sherilyn A. Tuazon, Ryan D. Cassaday, Theodore A. Gooley, Brenda M. Sandmaier, Leona A. Holmberg, Stephen D. Smith, David G. Maloney, Brian G. Till, Daniel B. Martin, Victor A. Chow, Joseph G. Rajendran, Darrell R. Fisher, Manuela C. Matesan, Sally J. Lundberg, Damian J. Green, John M. Pagel, Oliver W. Press, Ajay K. Gopal
Summary: Autologous hematopoietic cell transplantation (AHCT) is a standard treatment for high-risk lymphoma, but often does not achieve long-term remissions. Research on using CD45-targeted antibody-radionuclide conjugate (ARC) preceding AHCT in lymphoma patients suggests potential improvement in outcomes by allowing curative doses of radiation with minimized toxicity. The use of ARC in conjunction with novel therapies or immunotherapies should be further explored based on the feasibility and tolerability shown in this study.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)
Article
Oncology
Solomon A. Graf, Ryan D. Cassaday, Karolyn Morris, Jenna M. Voutsinas, Qian Vicky Wu, Sanaz Behnia, Ryan C. Lynch, Elizabeth Krakow, Heather Rasmussen, Thomas R. Chauncey, Sandra Kanan, Lorinda Soma, Stephen D. Smith, Ajay K. Gopal
Summary: This prospective study investigated the efficacy of ibrutinib monotherapy in 20 patients with histologically transformed diffuse large B-cell lymphoma, showing objective responses in 35% of patients with a median progression-free survival of 4.1 months. Ibrutinib demonstrated favorable tolerability and promising activity in this setting with limited treatment options, suggesting its potential utility as a bridge to more definitive treatments.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2021)
Editorial Material
Oncology
Stephen D. Smith, Ajay K. Gopal
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Hematology
Chaitra Ujjani, Mazyar Shadman, Ryan C. Lynch, Brian Tu, Philip A. Stevenson, Caitlin Grainger, Haiying Zhu, Joshua A. Hill, Meei-Li Huang, Leslie Nielsen, Christina Poh, Tyler Sorensen, Ajay K. Gopal, Edus H. Warren, Brian G. Till, Sydney Lee, Daria Gausman, Stephen D. Smith, Ted Gooley, Alex Greninger
Summary: This study found that SARS-CoV-2 vaccine efficacy was lower in chronic lymphocytic leukemia (CLL) patients, with decreased rates of seroconversion and lower antibody levels compared to healthy controls. The results from the Roche anti-S assay and neutralization activity were similar. Durable immune responses were observed up to six months, and booster shots were effective in improving the immune response in patients who had a response. The absence of normal B cells, commonly seen in CLL patients receiving certain treatments, was a strong predictor of lack of seroconversion.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
M. Lia Palomba, Brian G. Till, Steven I. Park, Franck Morschhauser, Guillaume Cartron, Reinhard Marks, Mahesh Shivhare, Wan-Jen Hong, Aparna Raval, Alice C. Chang, Elicia Penuel, Leslie L. Popplewell
Summary: This study assessed the safety, tolerability, and efficacy of atezolizumab plus obinutuzumab in patients with R/R DLBCL and FL. The combination treatment showed acceptable safety profile and demonstrated a certain level of efficacy in both FL and DLBCL cohorts.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Biochemistry & Molecular Biology
Zibing Wang, Yuqing Liu, Ling Peng, Brian Till, Yuwei Liao, Shumin Yuan, Xiang Yan, Lin Chen, Qiang Fu, Zhihai Qin
Summary: The role of B cells in the anti-tumor immune response is controversial. An increase in the number of B cells in the peripheral blood of some tumor patients has been associated with poor immunotherapy efficacy. This study suggests that CD11b(+) myeloid cells promote B cell proliferation, activation, and survival, and targeting B cells may increase the efficacy of immunotherapy in tumor-bearing hosts.
Article
Oncology
Yonghao Yang, Jun Li, Brian G. Till, Jun Wang, Bicheng Zhang, Hanping Wang, Hao Huang, Tiepeng Li, Quanli Gao, Hongle Li, Zibing Wang
Summary: Combination regimens based on PD-1 blockade have become common in cancer treatment, improving efficacy but leading to more complex and severe adverse events. A patient with gallbladder cancer experienced a TEN-like reaction after receiving camrelizumab in combination with apatinib, showing resistance to methylprednisolone but gradual improvement with IVIg. This reaction highlighted the important role of CD4+ and CD8+ T cells, suggesting further research is needed to understand the exact pathophysiologic mechanisms and management strategies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Mengchao An, Wenkang Wang, Jie Zhang, Brian G. Till, Lingdi Zhao, Hao Huang, Yonghao Yang, Tiepeng Li, Lu Han, Xiaojie Zhang, Peng Qin, Yunjian Wang, Min Zhang, Hong Cui, Quanli Gao, Zibing Wang
Summary: This study aimed to investigate the association between HBV DNA level, antiviral therapy, and survival outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with anti-PD-1 immunotherapy. The results showed that HBV DNA level was not significantly associated with survival outcomes, but antiviral therapy significantly improved overall survival.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Shumin Yuan, Ling Peng, Yuqing Liu, Brian G. Till, Xiang Yan, Jie Zhang, Liping Zhu, Huijuan Wang, Shaokai Zhang, Hongle Li, Quanli Gao, Zibing Wang
Summary: Retrospective analysis suggests that low-dose anlotinib may be an effective and well-tolerated anti-angiogenesis partner for combination therapy in advanced non-small cell lung cancer (NSCLC) patients.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Lorena Panaite, Qian Vicky Wu, Jenna Voutsinas, Erin Mullane, Victor A. Chow, Ryan C. Lynch, Chaitra S. Ujjani, Stephen D. Smith, Ajay K. Gopal, Christina Poh, Lorenzo Iovino, Cameron J. Turtle, David G. Maloney, Brian G. Till, Jordan Gauthier, Mazyar Shadman
Summary: Cytopenias following CAR-T therapy are important adverse events that have been less studied. Our analysis of patients with large cell lymphoma receiving axi-cel revealed that severe cytopenias were observed in a high percentage of patients, particularly among non-responders.
LEUKEMIA & LYMPHOMA
(2022)
Article
Cell Biology
Lorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, Lorena Panaite, Erin Mullane, Ryan C. Lynch, Chaitra Ujjani, Stephen D. Smith, Ajay K. Gopal, Brian G. Till, Filippo Milano, Victor Chow, Jordan Gauthier, Cameron J. Turtle, David G. Maloney, Mazyar Shadman
Summary: This single-institution study analyzed the impact of multiple variables on the outcomes of CAR-T therapy. The study showed that CAR-T treatment should be continued for DLBCL patients who do not respond to immediate pre-CAR-T therapy. Additionally, bulky disease and high LDH are risk factors for poor treatment outcomes.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2022)
Article
Hematology
Ryan C. Lynch, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Brian Till, Vikram M. Raghunathan, Stefan Alig, Ash A. Alizadeh, Avanti Gulhane, Delphine L. Chen, Yolanda Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Sarith Keo, Kaitlin Verni, Hongyan Du, Jacquelin Vandermeer, Ashley Gaston, Heather Rasmussen, Paul Martin, Edmond Marzbani, Jenna Voutsinas, Ajay K. Gopal
Summary: This study investigated the concurrent administration of pembrolizumab with chemotherapy in untreated classic Hodgkin lymphoma, showing promising safety and efficacy. Although some patients experienced adverse events, the overall response rate was 100% with a complete response rate of 90%.
Article
Hematology
Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren, Mazyar S. Shadman, Andrei Shustov, Brian G. Till, Chaitra S. Ujjani, Edward N. Libby, Mary Philip, Hilary Coye, Christen N. Martino, Sandra L. Bhark, Karolyn Morris, Heather Rasmussen, Sanaz Behnia, Jenna Voutsinas, Ajay K. Gopal
Summary: The study aimed to evaluate the safety and activity of dose-dense brentuximab vedotin combined with ifosfamide, carboplatin, and etoposide in second-line treatment of relapsed or refractory classical Hodgkin lymphoma. The results showed that the regimen was an effective salvage treatment despite a lower complete response rate than the preset target, and it can be considered for second-line therapy in transplantation-eligible patients under 60 years old.
LANCET HAEMATOLOGY
(2021)
Article
Medicine, General & Internal
Marthilde Brzycki, Robert Richard, Nicholas Burwick, Solomon Graf, Craig O'Brien, Daniel Wu, Thomas R. Chauncey
Summary: Autologous hematopoietic cell transplantation is a standard of care for most patients with newly diagnosed multiple myeloma, but the safety of undergoing this procedure after COVID-19 infection is not well understood.
CLINICAL CASE REPORTS
(2021)